

Syngene

Ref: Syn/CS/SE/RPT/2021-22/May/20

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 &
3, Bommasandra Industrial Area, IV
Phase, Jigani Link Road, Bengaluru
560 099, Karnataka, India
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

May 25, 2021

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Subject: Submission of Disclosure on Related Parties Transactions

Pursuant to Regulation 23(9) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we hereby submit disclosure of Related Party Transactions on Consolidated basis for the half-year ended March 31, 2021, drawn in accordance with the applicable Accounting Standards.

The above-mentioned disclosure will also be available on website of the Company www.syngeneintl.com.

Kindly take the above information on record.

Thanking You,

Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

Priyadarshini Mahapatra
Company Secretary and Compliance Officer

DISCLOSURE OF RELATED PARTY TRANSACTIONS – ON CONSOLIDATED BASIS

In pursuance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

A. List of key management personnel

SI No	Name of the related party	Relationship
(a)	Kiran Mazumdar Shaw	Chairperson (w.e.f. 1 April 2020)
		Chairperson and Managing Director (till 31 March 2020)
(b)	John Shaw	Non-executive director
(c)	Jonathan Hunt	Managing Director and Chief Executive Officer (w.e.f. 1 April 2020)
		Director and Chief Executive Officer (till 31 March 2020)
(d)	Catherine Rosenberg	Non-executive director
(e)	Bala S. Manian	Independent director (till 15 July 2020)
(f)	Carl Decicco	Independent director
(g)	Paul Blackburn	Independent director
(h)	Sharmila Abhay Karve	Independent director
(i)	Vijay Kuchroo	Independent director
(j)	Vinita Bali	Independent director
(k)	Sibaji Biswas	Chief Financial officer (w.e.f. 18 December 2019)
(l)	M B Chinappa	Chief Financial officer (till 17 December 2019)
(m)	Priyadarshini Mahapatra	Company Secretary (w.e.f. 24 July 2019)

B. OTHER RELATED PARTIES

SI No	Name of the related party	Relationship
(a)	Biocon Limited	Holding Company
(b)	Biocon Biologics Limited (formerly known as Biocon Biologics India Limited)	Fellow subsidiary
(c)	Biocon SDN. BHD	Fellow subsidiary
(d)	Biocon Biologics UK Limited (formerly known as Biocon Biologics Limited)	Fellow subsidiary
(e)	Biocon Biologics Inc.	Fellow subsidiary
(f)	Biocon Biologics Do Brasil Ltda	Fellow subsidiary
(g)	Biocon Biologics FZ-LLC	Fellow subsidiary
(h)	Biocon Biologics Healthcare SDN. BHD (formerly known as Biocon Healthcare SDN. BHD)	Fellow subsidiary
(i)	Bicara Therapeutics Inc.	Fellow subsidiary (upto 9 January 2021)
		Associate of Holding Company (w.e.f. 10 January 2021)
(j)	Biofusion Therapeutics Limited	Fellow subsidiary
(k)	Biocon Biosphere Limited	Fellow subsidiary
(l)	Biocon Pharma Limited	Fellow subsidiary
(m)	Biocon Pharma Inc.	Fellow subsidiary
(n)	Biocon Pharma Ireland Limited	Fellow subsidiary
(o)	Biocon Pharma Malta Limited	Fellow subsidiary
(p)	Biocon Pharma Malta I Limited	Fellow subsidiary
(q)	Biocon Pharma UK Limited	Fellow subsidiary
(r)	Biocon SA	Fellow subsidiary
(s)	Biocon FZ LLC	Fellow subsidiary
(t)	Biocon Academy	Fellow subsidiary
(u)	Biocon Foundation	Trust in which a director is a trustee
(v)	Narayana Hrudayalaya Limited	Enterprise in which a director of the Company is a member of board of directors
(w)	Immuneel Therapeutics Private Limited	Enterprise in which a director of the Company is a member of board of directors
(x)	Jeeves	Enterprise in which relative to a director of the Company is proprietor

II. TRANSACTIONS WITH RELATED PARTY

(Amount in Indian Rupees Million)

Particulars	Transaction/ Balances	Half year ended 31 March 2021	Half year ended 31 March 2020
Key management personnel	Salary and perquisites [refer note (i) and (ii) below]	38	49
	Sitting fees and commission	12	11
	Outstanding as at the year end		
	- Trade and other payables	5	5

Particulars	Transaction/ Balances	Half year ended 31 March 2021	Half year ended 31 March 2020
Holding company	Rent	31	34
	Power and facility charges [refer note (iii) below]	81	134
	Purchase of goods	2	-
	Other expenses reimbursed to	58	55
	Purchase of assets	-	31
	Sale of services	28	42
	Rent and facility charges	11	-
	Other expenses incurred on behalf	9	-
	Outstanding as at the year end		
	- Trade and other payables	65	217
- Rent deposits	23	23	
- Trade and other receivables	31	34	
Guarantee given to Central Excise Department	148	148	
Fellow subsidiaries	Sale of services	296	214
	Rent and facility services	164	117
	Purchase of assets	-	56
	Purchase of goods	-	- *
	Other expenses incurred on behalf	7	-
	Other expenses reimbursed to	8	-
	Outstanding as at the year end		
	- Trade and other payables	1	51
- Trade and other receivables	362	328	
Other related parties	Sale of services	282	- *
	Health services availed	3	2
	Contribution towards Corporate Social Responsibility	10	64
	Staff welfare expenses	2	2
	Investment in compulsorily convertible debentures	-	100
	Allotment of equity shares	100	-
	Outstanding as at the year end		
	- Trade and other payables	- *	-
	- Trade and other receivables	280	-

* Less than Rs. 0.5 million.

Notes:

(Amount in Indian Rupees Million)

(i) The remuneration to the key managerial personnel does not include the provisions made for gratuity and compensated absences, as they are determined on an actuarial basis for the Company as a whole.

(ii) Share based compensation expense allocable to key management personnel is Rs. 82 (Half year ended 31 March 2020: Rs.61) for the half year ended 31 March 2021, which is not included in the remuneration disclosed above.

(iii) Effective from 1 October 2006, the Company has entered into an arrangement for lease of land on lease basis and a service agreement with 'Biocon SEZ Developer' of Biocon Limited for availing certain facilities and services. The facility charges of Rs. 74 (Half year ended 31 March 2020: Rs.51) and power charges (including other charges) of Rs. 7 (Half year ended 31 March 2020: Rs. 83) have been charged by Biocon Limited for the half year ended 31 March 2021.

(iv) All transactions with these related parties are priced on an arm's length basis and none of the balances are secured.